Abstract 383P
Background
The body mass index (BMI) before therapy shows a variety of progression free survival (PFS), it was said in the BMI study <18.5 kg/m2, had a worse progression free survival, compared to BMI 18.5-24.9 kg/m and BMI >24.9 kg/m2. The neutrophil lymphocyte ratio before therapy showed a variety of progression free survival (PFS). It was said that NLR ≥ 3 patients study have a better progression free survival compared to those < 3, but these results are still contradictory. The aim of this study was to determine body mass index and neutrophil to lymphocyte ratio before therapy to predict 3-year progression free survival in patients with locally advanced nasopharyngeal carcinom.
Methods
Patients with locally advanced nasopharyngeal carcinoma (N=289) from 2015 until 2017 who underwent chemoradiation with and without adjuvant or neoadjuvant chemotherapy were enrolled. Body mass index before therapy was classified as <18.5 (underweight), 18.5-24.9 (normal), and >24.9 (overweight or obese) and the neutrophil to lymphocyte ratio before therapy was categorized as ≥3 and <3, using the Cox proportional hazard and Kaplan-Meier models.
Results
Body mass index 18.5-24.9 and 24.9 on Cox regression has a better 3-year PFS with adjusted hazard ratio (HR = 0.219; CI = 1.43-1.59; p = 0.025 and HR = 0.136 ; CI = 1.51-1.76; p = 0.025 ), BMI <18.5 indicates a lower 3-year PFS (HR=1.644; CI=1.28-1.56; P=0.001). While NLR ≥3 before therapy had a better 3-year PFS (HR=0.152; CI 1.37-1.53, p=0.001) than NLR <3 (HR=1.603; CI 1.52-1.69, p=0.013.
Conclusions
Patients with BMI<18.5 before therapy had a lower 3-year PFS, and BMI>24.9 had a 3-year higher PFS than the normal weight group and NLR ≥3 had a higher PFS than under 3. This study provides a good understanding better between BMI and PFS and NLR and PFS, but further research is needed to confirm the result in different populations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract